Amgen (AMGN) Presents New Repatha Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/20/2026

1. NVDA
2. SPY
3. EYPT
4. AMZN
5. CRWV
6. META
7. TSLA
8. IRON
9. SPCX
10. STLD

Go back to Amgen (AMGN) Presents New Repatha Data

Amgen (AMGN) data supports long-term growth potential says analyst

November 8, 2022 10:37 AM EST

Amgen (NASDAQ: AMGN) reported new analysis from its Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha on Tuesday, stating that the data reinforces long-term efficacy and the consistent safety profile.

Amgen shares are up more than 5% following the... More

Amgen (AMGN) Climbs 6.4%

November 8, 2022 10:20 AM EST

Amgen (NASDAQ: AMGN) Climbs 6.4%

... More

Amgen (AMGN) PT Raised to $325 at Jefferies Following AMG-133 Update

November 8, 2022 8:16 AM EST

Jefferies analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $325.00 (from $300.00) while maintaining a Buy rating.

The analyst commented, "AMGN update looks positive and consistent w/ our Buy, with valuation likely to go up with AMG-133 for obesity... More